Literature DB >> 1710786

Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.

M Shahid1, C D Nicholson.   

Abstract

The species dependent variation in the cardiotonic activity of selective cyclic nucleotide phosphodiesterase (PDE) isoenzyme inhibitors was examined by comparing the inotropic and PDE inhibitory effects of Org 30029 (N-hydroxy-5,6-dimethoxy-benzo[b]thiophene-2-carboximidamide HCl), 3-isobutyl-1-methyl-xanthine (IBMX), milrinone and rolipram in rat and rabbit ventricular myocardium. The relative activities of PDE isoenzymes in rat and rabbit cardiac ventricle were also examined to assess the role of the different PDE subtypes in modulating contractile force in the two species. In rabbit papillary muscles, IBMX, Org 30029 and milrinone increased contractile force whilst rolipram was inactive. The rank order of potency of the active compounds was Org 30029 greater than IBMX greater than milrinone. Only Org 30029 and IBMX produced significant positive inotropic responses in rat papillary muscles, milrinone and rolipram being inactive. However, large positive inotropic responses were obtained in rat papillary muscles when milrinone and rolipram were tested in combination. In rabbit papillary muscles, the positive inotropic action of milrinone was markedly potentiated by rolipram. Four main types of PDE (I, II, III, IV) isoenzymes were resolved, by DEAE-sepharose or Mono-Q ion-exchange chromatography, from both rat and rabbit cardiac ventricular tissue. In rabbit, Ca2+/calmodulin dependent PDE (PDE I) and cyclic GMP inhibited PDE (PDE III) were the dominant cAMP activities. In contrast, cyclic GMP stimulated PDE (PDE II), PDE III and cGMP insensitive PDE (PDE IV) represented the main cAMP activities in rat cardiac ventricle. The inhibitory effects of Org 30029, IBMX, milrinone and rolipram on PDE isoenzymes from rat and rabbit cardiac ventricle were essentially similar.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1710786     DOI: 10.1007/bf00175715

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

1.  The 'calcium sensitising' effects of ORG30029 in saponin- or Triton-skinned rat cardiac muscle.

Authors:  D J Miller; D S Steele
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

2.  Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activities in rabbit ventricular myocardium: relations to post-natal maturation.

Authors:  P A Kithas; M Artman; W J Thompson; S J Strada
Journal:  J Mol Cell Cardiol       Date:  1989-05       Impact factor: 5.000

3.  Analysis of responses to a selective phosphodiesterase III inhibitor, SK&F 94120, on isolated myocardium, including human ventricular myocardium from "end-stage" failure patients.

Authors:  R W Gristwood; T A English; J Wallwork; K A Sampford; D A Owen
Journal:  J Cardiovasc Pharmacol       Date:  1987-06       Impact factor: 3.105

4.  Particulate cyclic 3',5'-nucleotide phosphodiesterase and calmodulin of cardiac muscle.

Authors:  G Ahluwalia; A R Rhoads; M Lulla
Journal:  Int J Biochem       Date:  1984

5.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

Authors:  M L Reeves; B K Leigh; P J England
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

6.  The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site.

Authors:  C D Nicholson; S A Jackman; R Wilke
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

7.  Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.

Authors:  M Shahid; I W Rodger
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

8.  Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.

Authors:  D Brunkhorst; H v der Leyen; W Meyer; R Nigbur; C Schmidt-Schumacher; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

9.  Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity.

Authors:  R W Gristwood; R J Eden; D A Owen; E M Taylor
Journal:  J Pharm Pharmacol       Date:  1986-06       Impact factor: 3.765

10.  The role of cyclic AMP and the dihydropyridine-sensitive channels on the mechanism of action of milrinone (Corotrope).

Authors:  C J Frangakis; C Lanni; K P Lasher; R G Bentley; A E Farah
Journal:  J Cardiovasc Pharmacol       Date:  1989-06       Impact factor: 3.105

View more
  25 in total

1.  Species differences in localization of cardiac cAMP-phosphodiesterase activity: a cytochemical study.

Authors:  L Okruhlicová; N Tribulová; J Styk; A Eckly; C Lugnier; J Slezk
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

Review 2.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

3.  Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  N Komas; C Lugnier; J C Stoclet
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

4.  The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors.

Authors:  M Shahid; R G van Amsterdam; J de Boer; R E ten Berge; C D Nicholson; J Zaagsma
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

5.  Nitric oxide synthase (NOS3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart. Regulation of NOS3 transcription in vitro and in vivo by cyclic adenosine monophosphate in rat cardiac myocytes.

Authors:  L Belhassen; R A Kelly; T W Smith; J L Balligand
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

6.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

7.  Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.

Authors:  T Bethke; W Meyer; W Schmitz; H Scholz; B Stein; K Thomas; H Wenzlaff
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

8.  Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  D G Wynne; P A Poole-Wilson; S E Harding
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

9.  Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.

Authors:  M Holbrook; S J Coker
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

10.  Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.

Authors:  J Schneider; E Beck; C Heers; C Conrad; D de Chaffoy de Courcelles; B Wilffert; T Peters
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.